Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 2

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

NCT05195632 · tracked via the Priya Life Science Taiwan tracker
Phase
Phase 2
Started
2022-06-02
Last updated
2026-05-01

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Encorafenib →Binimetinib →

Encorafenib: Hard capsule

Binimetinib: Film-coated tablet

Study summary

This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either previously untreated or have had one line of prior therapy in metastatic setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: If a participant has a BRAF V600E mutational status confirmed as per local assessment, the participant might enter the main screening directly. All the following inclusion criteria must be met for a participant to be eligible to be included in this study: 1. Provide a signed and dated screening Informed Consent Form (ICF). 2. Chinese male or female with age ≥ 18 years old for China mainland and ≥ 20 years old for Taiwan at the time of the screening informed consent. 3. Documented histology- and/or cytology-confirmed metastatic unresectable Non-small cell lung cancer (NSCLC (i.e. Adenocarcinoma (ADC), large cell carcinoma, squamous cell carcinoma (SCC)). 4. Presence of B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation in tumor tissue previously determined by a local assay at any time prior to screening or by the central laboratory. 5. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archived or newly obtained) for central prospective laboratory testing of BRAF mutation status and comparison of central BRAF V600E testing in the clinical study to BRAF V600E testing with a candidate companion diagnostic. 6. BRAF- and Mitogen-activated protein kinase kinase (MEK)-inhibitor treatment-naïve participants and previously untreated or have had one line of prior therapy in metastatic setting. 7. At least one measurable disease as per investigator assessment, as defined by RECIST v1.1, which has neither been irradiated nor biopsied during the screening period. 8. Life expectancy ≥ 3 months. 9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 10. Adequate hematologic function at screening and baseline. 11. Adequate hepatic function at screening and baseline. 12. Adequate renal function at screening and baseline. 13. Able to comply with the study protocol as per investigator assessment including oral drug intake, complying scheduled visits, treatment plan, laboratory tests and other study procedures. 14. Women are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or child-bearing potential women must agree to take appropriate precautions to avoid pregnancy. 15. Men must agree not to father child until 90 days after the last dose of the study treatment. Exclusion Criteria: Participants meeting any of the following criteria are not eligible to be included in this study: 1. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs (encorafenib and binimetinib), or their excipients. 2. Documented Anaplastic lymphoma kinase (ALK) fusion oncogene, Reactive oxygen species (ROS) rearrangement or Epidermal growth factor receptor (EGFR) sensitizing or driver mutation. 3. Participants who have received more than one prior line of systemic therapy. 4. Receipt of anti-cancer medications or investigational drugs within the specified intervals before the first administration of study treatment. 5. Symptomatic brain metastases or other active Central nervous system (CNS) metastases. 6. Leptomeningeal disease. 7. Participant has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment. 8. Current use of prohibited medication ≤ 1 week prior to start of the study treatment and/or concomitantly. 9. Impairment of gastrointestinal function or disease which may significantly alter the absorption of oral study treatment. 10. Impaired cardiovascular function or clinically significant cardiovascular diseases 11. History of thromboembolic or cerebrovascular events within 3 months prior to starting the study treatments 12. History or evidence of retinal pathology considered as risk factor for Retinal vein occlusion (RVO) or neovascular macular degeneration. 13. Concurrent neuromuscular disorder associated with the potential of elevated Creatine phosphokinase (CPK) 14. Participants with active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) or any other severe viral active infection (e.g. SARS-CoV-2 infection) 15. Evidence of active, non-infectious pneumonitis, history of interstitial lung disease that required oral or intravenous glucocorticosteroids for management. 16. Known history of a positive test for Human immunodeficiency virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS). Testing for HIV must be performed at sites where mandated locally. 17. Participants who have had major surgery (e.g. inpatient procedure with regional or general anesthesia) within 6 weeks prior to start of study treatment. 18. Participants with concurrent or history of another malignancy within 2 years of study entry Except: 1. Bowen's disease 2. Cured basal cell or cutaneous squamous cell carcinoma (CuSCC) 3. Gleason 6 prostate cancer 4. Treated in-situ carcinoma of cervix 19. Participant's conditions that contraindicates the use of study treatments and may affect interpretation of results or may render the participant at high risk from treatment complications. 20. Pregnant (confirmed by positive serum beta-human chorionic gonadotropin (ß-HCG) test), lactating or breast-feeding women. 21. Is a family member of the investigator or any associate, colleague, and employee assisting in the conduct of the study (secretary, nurse, technician). 22. Is in a position likely to represent a conflict of interest.

Primary outcome measure(s)

  • Safety Lead-In (SLI) Part: Incidence of Dose-limiting toxicities (DLTs) — Cycle 1; Each cycle is 28 days
    Incidence of DLTs experienced during the Cycle 1 (days 1 to 28) after the first dose of study treatment. DLT rate defined as the number of DLT-evaluable participants with DLTs in the first 28 days after first dose of study treatment in the SLI (DLT-evaluation period), divided by the number of DLT-evaluable participants.
  • Pivotal Part: Confirmed objective response rate (cORR) — Cycle 1 Day 1 through safety follow-up visit (30 days after end of treatment (EOT) visit or 7 days after EOT visit/last dose if EOT not performed), approximately up to 18 months. Each cycle is 28 days.
    cORR defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) as determined by Independent Central Review (ICR) of radiographic disease assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Proportion of patients who have achieved a confirmed Best Overall Response (cBOR) of CR or PR as determined by per RECIST v1.1 and corresponding exact two-sided binomial 95% Confidence interval (CI).

Trial sites (34)

FacilityCityRegionStatus
Beijing Cancer Hospital Beijing China
Beijing Chest Hospital, Capital Medical University Beijing China
Peking University First Hospital Beijing China
The First Hospital of Jilin University Changchun China
Xiangya Hospital Central South University Changsha China
Sichuan Cancer Hospital Chengdu China
Chongqing University Cancer Hospital Chongqing China
The Second Hospital of Dalian University Dalian China
Fujian Medical University Union Hospital Fuzhou China
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian) Fuzhou China
Guangdong Provincial People's Hospital Guangzhou China
Sun Yat-sen University Cancer Center Guangzhou China
Hainan General Hospital Haikou China
First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China
Zhejiang Cancer Hospital Hangzhou China
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital Hangzhou China
Harbin Medical University Cancer Hospital Harbin China
Shandong Cancer Hospital Jinan China
The First Affiliated Hospital of Jinzhou Medical University Jinzhou China
Linyi Cancer Hospital Linyi China
The First Affiliated Hospital of Nanchang University Nanchang China
Guangxi Medical University Affiliated Tumor Hospital Nanning China
Liaoning Cancer Hospital & Institute Shenyang China
The First Hospital of China Medical University Shenyang China
Peking University Shenzhen Hospital Shenzhen China
The Fourth Hospital of Hebei Medical University Shijiazhuang China
Shanxi Provincial Cancer Hospital Taiyuan China
Tianjin Cancer Hospital Airport Hospital Tianjin China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
Union Hospital Tongji medical college Huazhong University of Science and Technology Wuhan China
The Northern Jiangsu People's Hospital Yangzhou China
Yantai Yuhuangding Hospital Yantai China
Henan Cancer Hospital Zhengzhou China
Taipei Veterans General Hospital Taipei Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05195632 on ClinicalTrials.gov ↗ ← All trials in Taiwan